Payment data and conditions
| Component | U.S. dollars, millions |
|---|---|
| Upfront at closing | 550 |
| Development and regulatory milestones | Up to 595 |
Both graphics use a zero-to-600 scale. The components sum to a maximum $1,145 million, rounded by the issuer to approximately $1.15 billion. Closing is expected by year-end, subject to customary conditions. Factual terms redrawn; no issuer artwork reproduced. No drug-sales or investment-return forecast.
Argenx plans to pay $550 million upfront for Unnatural Products, a California drug developer. The acquisition announced November 9 would give the antibody specialist another route to medicines people could take by mouth. [1]
The Nasdaq-listed company (ARGX) is buying a discovery business, with up to $595 million more tied to development and regulatory milestones. A successful laboratory idea still has to become a medicine that works safely in patients. [1]
A different way to reach disease
Unnatural Products designs compounds called macrocyclic peptides. Its aim is to combine precise targeting with oral delivery, including targets inside cells that are difficult for conventional drugs to reach. Those are the company's research goals, rather than established benefits of an approved product. [3]
Its process repeatedly designs, makes and tests compounds, using the results to improve the next round. Finding a molecule that binds its target is only part of the challenge; it also needs properties that let it reach that target in the body. The company describes improving potency, selectivity and permeability together. [4]
“creates new possibilities for oral and long-acting medicines”
Karen Massey, argenx CEO, November 9, 2026 [1]
That could broaden what argenx can sell over time. Its existing VYVGART medicines are delivered through infusions or injections. An effective oral option could offer a different treatment experience, but the acquisition announcement establishes no approved oral replacement. [2] [1]
From a partnership to ownership
The two companies already had a research agreement, publicly announced in July 2025. Unnatural Products would work on targets chosen by argenx, which held an option to take resulting products into further development and commercialization. The arrangement also included an equity investment. [3]
That earlier agreement carried potential payments of approximately $1.5 billion across research, development, regulatory and commercial milestones and options, plus royalties. It was a collaboration ceiling, not cash already paid or an additional acquisition bill. [3]
A growing business pays for the search
Argenx has an established business behind this research. VYVGART generated about $1.7 billion in worldwide net product sales in the September quarter, up 54% from a year earlier. That gives the company a commercial foundation while it develops other medicines. [2]
But it has already been spending heavily on expansion. At September 30, argenx reported $2.6 billion in cash and cash equivalents and $1.1 billion in current financial assets. Those balances followed approximately $2.1 billion spent buying Forte Biosciences, net of acquired cash. They are a dated balance-sheet snapshot, not today's cash balance. [2]
Both boards approved the UNP deal, with closing expected by year-end subject to conditions. Milestones limit some of the payment until progress is made; they do not protect the upfront investment if the research disappoints. [1]
The market connection For ARGX, the opportunity is a wider range of future medicines. The cost arrives before those possible sales, leaving scientific progress to determine whether the new research route earns its place.